Essay
KKR isn't buying Integer cheap. It's buying what public markets couldn't underwrite
Integer Holdings makes the components inside pacemakers and catheters for Medtronic and Boston Scientific. A guidance cut and an activist campaign crushed its stock before KKR agreed to buy it for $5.7 billion.
Integer Holdings is not a company most people have heard of, which is the point of the company. It designs and manufactures the components that go inside other people’s medical devices: batteries and connectors for pacemakers, catheters, the guts of cardiac rhythm and neuromodulation products sold under the Medtronic, Boston Scientific and Johnson & Johnson names. It is a contract development and manufacturing organisation, a CDMO, meaning its job is to be invisible. On 3 August 2026, KKR agreed to buy it for $127 a share, an all-cash deal valued at an enterprise value of about $5.7 billion. To understand why KKR wanted it now, you have to look at what happened to Integer’s stock over the eight months before the deal, not at the premium in the press release.
The stock did not fall because the business broke
In December 2025, Irenic Capital, an activist fund founded by a former Elliott Management portfolio manager, disclosed a stake above 3% in Integer and pushed for board changes and a sale process. Around the same time, Integer cut its 2026 growth outlook hard: from a typical 6-8% organic growth target down to a range of -2% to 2%. The stock dropped roughly 40% on the news, per CNBC’s reporting on the activist campaign, a reaction management called overdone given it framed the slowdown as a temporary air pocket ahead of a return to normal growth in 2027.
Here is the part that actually explains the deal. Integer cannot tell public investors which customer programs are driving its numbers, because its contracts with Medtronic, Boston Scientific and the rest are confidential. When the guidance cut hit, the market had no way to check whether it was one lost program or a broader problem, so it priced in the worst case. Irenic’s own argument, echoed by other holders, was that this opacity is structural to the CDMO model and will keep punishing the stock every time there is bad news, regardless of what is actually happening inside the business. By March, Irenic had two allies on the board. By 30 April, the board launched a formal strategic review, which it described in its own announcement as weighing “a sale, merger, or strategic business combination” against staying independent.
That is the opportunity KKR is underwriting. Not a cheap asset, a mispriced one, mispriced specifically because the public market structurally cannot see what a private owner can.
What KKR actually said it is buying
KKR partner Max Lin described Integer as “an exceptional platform with highly differentiated capabilities across a global manufacturing footprint, a track record for quality and reliability, and a talented team operating in attractive, durable end-markets,” per Sharecast’s coverage of the announcement. Strip the adjectives and the thesis is straightforward: sole-source relationships with the three biggest cardiac and neuromodulation device makers in the world are hard to replace, the end markets grow with an aging population regardless of any one year’s guidance wobble, and the thing standing between the current stock price and the business’s real value is the disclosure burden of being public, not the business itself.
KKR is paying for that with a mix of equity from its managed funds and committed debt, arranged by Citi, KKR Capital Markets, Barclays, UBS and Jefferies according to the deal announcement, on top of the $1.2 billion of debt Integer already carries at 3.2 times EBITDA, per Integer’s own trading update, which puts the purchase price at about 15 times EBITDA. Working back from those figures myself, not from any single source, KKR’s own equity check likely lands closer to $4.3 to $4.5 billion, with the rest funded by lenders betting on the same recovery thesis; treat that number as my estimate, not a disclosed figure. On the price itself: the 51.8% premium in the headline is measured against Integer’s stock before the strategic review was announced, not against the price once a Wall Street Journal report made a deal look imminent, at which point the real premium was closer to 5%. Worth knowing, not worth dwelling on. Everyone pricing this deal already knew the stock had run ahead of the announcement.
The same firm bought two very different things this quarter
KKR also closed its acquisition of Arctos Partners, the sports-franchise investor, in the same reporting period. The two deals look nothing alike, and the differences are the more useful lesson than either deal on its own.
| Integer Holdings | Arctos Partners | |
|---|---|---|
| What it is | CDMO manufacturing components inside Medtronic, Boston Scientific and J&J devices | Investor in professional sports franchise stakes, plus a GP-solutions and secondaries business |
| Deal value | $5.7 billion enterprise value | $1.4 billion initial value, AUM grew from $15 billion to $20 billion between signing and close |
| How KKR paid | 100% cash, funded by fund equity plus committed acquisition debt | Cash and equity: about $300 million cash, $900 million equity to existing shareholders, $200 million held-back employee equity, no acquisition debt |
| Why the seller wanted KKR | An activist-driven strategic review after a guidance cut, opacity from customer confidentiality kept the market from underwriting the business fairly | Founders wanted KKR’s distribution into wealth and institutional channels to keep scaling a young asset class |
| What the return depends on | The “opacity discount” closing once the business is private, plus debt paydown and margin recovery | Continued AUM growth in a still-immature category, cross-sell through KKR’s existing platform |
| The mispricing KKR is exploiting | Public markets cannot see through confidentiality obligations Integer is bound by | Public markets have no comparable to benchmark sports-stakes investing against, so it stayed too small to attract this kind of buyer until now |
Put side by side, the two deals share a logic even though the financing looks opposite. In both cases KKR is paying for something the public market structurally cannot price correctly, information locked behind NDAs in Integer’s case, a genuinely new asset class with no public comparables in Arctos’s case. The capital structure follows the asset: a mature, cash-generative manufacturer gets leverage layered on top of underwriting; a young, fast-growing manager gets equity and patience. Both bets are really the same bet, that KKR’s edge this quarter is not access to cheap capital, it is a willingness to underwrite what public investors cannot.